Twin Health Patent Portfolio Analysis

Fifty-nine million, one point in time

The round closed on 15 September 2026: $59M, with Temasek, Sequoia Capital, Peak XV Partners, Perceptive Advisors and ICONIQ Growth named. That is the visible event, and it is the least interesting date in this file. Twin Health was founded in 2018. The first patent filing came on 13 August 2020. The most recent published filing is dated 1 April 2024, twenty-nine months before the money arrived.

So the pulse you are looking at sits at the end of a six-year record, not the start of one. Anything filed after April 2024 is still inside the publication delay and cannot be read yet. Everything that follows is drawn from what was already public before the investors signed. The useful question is what that earlier record contains, and whether it is thin or simply concentrated.

Six ticks, two of them already solid

Six families. Two granted, four published and pending. That is a 33 percent grant rate, and it is a small arc by any measure. But the two solid marks are enforceable today, and the filing dates behind them run one per year without a gap: 2020, two in 2021, then 2022, 2023, 2024. No burst, no pause, no abandonment of the line.

The titles of the recent filings are consistent with each other. Capturing and measuring timeliness, accuracy and correctness of health and preference data in a digital twin enabled precision treatment platform. Metabolic health using a precision treatment platform enabled by whole body digital twin technology. Dynamically modeling the effect of food items and activity on a patient's metabolic health. The same subject, returned to annually, narrowed each time.

Six ticks is not a portfolio built for breadth. It is one built for return visits.

Seventeen dots, one of them on everything

Seventeen inventors are named across the six families. That is roughly three names per filing, which suggests teams rather than lone drafters. But the distribution is not even. Terrence Chun Yin Poon appears on six of six. Jahangir Mohammed appears on five. Frederick Hadley appears on four. The rest appear once or twice and then disappear from the record.

A portfolio with one name on every family has a spine. Whatever the disclosed subject matter is, one person has been present for all of it since August 2020 and has watched each filing follow the last. The other fourteen names read as contributors brought in for specific work. Concentration like this is legible: the technical continuity sits with three people, and the record shows exactly who.

The same groups, at a different scale

Set the six families against the other assignees filing in the same CPC groups over the last five years and the arithmetic is unkind. Philips filed 1,147. Samsung, 644. Zhejiang University, 614. Biosense Webster Israel, 388. Medtronic, 330. Huawei, 282. Twin Health is the small circle, and no reading of the chart makes it larger.

Count is not the only variable, and in a space this populated it may not be the decisive one. Six families filed annually against a moving target are a different instrument from six hundred filed across a portfolio of programmes. What matters is where the claims land and how narrowly they are drawn. But the picture is honest about the setting: this is a well-attended area, and Twin Health arrived in 2020.

Who has already read the file

Citations run the other way from filings. Roche Diabetes Care cites these filings seventeen times. Kpn Innovations, eleven. Dexcom, eight. Hoffmann La Roche, seven. Unitedhealth, five. Forty-eight citations in total, from five organisations, pointing back at a portfolio of six families.

That ratio is the point the earlier stages were building toward. A small portfolio from a company founded in 2018 is being cited by organisations considerably older and larger than it. Citation is not endorsement and it is not proof of scope, but it does establish that the disclosures were found, examined and considered relevant by people filing in the same groups. Six families were enough to be read.

Forty-eight citations against six families is a density the count alone will never show you.

What the next publication will settle

Here is what the record actually says. One inventor on all six families. One filing a year since 2020, on the same subject, returned to and narrowed. Two grants already in force. Five outside organisations citing the work forty-eight times. And a twenty-nine-month publication gap between the last public filing and the round.

The portfolio is small because it was built narrow, not because it stopped. Whatever was filed between April 2024 and the September 2026 close is still unpublished, and it will either continue the annual cadence or break it. That is the single fact that distinguishes a deliberate line from one that ended quietly, and it becomes readable on its own schedule.